Suggested remit - To appraise the clinical and cost effectiveness of eculizumab within its marketing authorisation for treating relapsing neuromyelitis optica spectrum disorders
Topic is suspended
Status Suspended
Process STA 2018
ID number 1271

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
02 September 2020 Expected publication
30 July 2020 Suspended. Topic is suspended
01 July 2020 The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps
16 May 2019 (14:00) Scoping workshop (Manchester)
21 March 2019 - 18 April 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance